

OPTIMA HEALTH PLAN

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-800-750-9692.** No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. If information provided is not complete, correct, or legible, authorization may be delayed.

Topical Rosacea Drugs

Drug Requested: (check applicable box below)

<input type="checkbox"/> Mirvaso [®] (brimonidine)	<input type="checkbox"/> Rhofade [®] (oxymetazoline)
<input type="checkbox"/> Soolantra [®] (ivermectin)	<input type="checkbox"/> Zilxi [®] (minocycline)

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy:** _____

Diagnosis: _____ **ICD Code, if applicable:** _____

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

☐ **For Mirvaso[®] and Rhofade[®] requests, ALL of the following criteria must be met:**

- ☐ Member is 18 years of age or older
- ☐ Member's quality of life has been impacted
- ☐ Member has **ONE** of the following diagnosis:
 - ☐ Persistent (non-transient) facial erythema (subtype erythematotelangiectatic rosacea)
 - ☐ Papulopustular lesions with persistent (non-transient) facial erythema (subtype erythematotelangiectatic rosacea)
- ☐ Member has tried and failed **at least 30 days** of therapy with **two (2)** of the following within the last 6 months (**submit chart notes documenting treatment failure**):

<input type="checkbox"/> Oral doxycycline hyclate	<input type="checkbox"/> Oral minocycline	<input type="checkbox"/> Oral tetracycline	<input type="checkbox"/> Topical retinoids (e.g., adapalene, tretinoin) (*requires prior authorization)
<input type="checkbox"/> metronidazole cream 0.75%, <input type="checkbox"/> metronidazole 0.75% gel <input type="checkbox"/> metronidazole 1% gel	<input type="checkbox"/> sodium sulfacetamide sulfur 10%/5% <input type="checkbox"/> sodium sulfacetamide sulfur 8%/4%	<input type="checkbox"/> azelaic acid gel 15%	

(Continued on next page)

☐ For Soolantra® and Zilxi® requests, ALL of the following criteria must be met:

- ☐ Member must have papulopustular rosacea and inflammatory lesions
- ☐ Member has tried and failed **at least 30 days** of therapy with **two (2)** of the following within the last 6 months (**submit chart notes documenting treatment failure**):

<input type="checkbox"/> Oral doxycycline hyclate	<input type="checkbox"/> Oral minocycline	<input type="checkbox"/> Oral tetracycline	<input type="checkbox"/> Topical retinoids (e.g., adapalene, tretinoin) (*requires prior authorization)
<input type="checkbox"/> metronidazole cream 0.75%, <input type="checkbox"/> metronidazole 0.75% gel <input type="checkbox"/> metronidazole 1% gel	<input type="checkbox"/> sodium sulfacetamide sulfur 10%/5% <input type="checkbox"/> sodium sulfacetamide sulfur 8%/4%	<input type="checkbox"/> azelaic acid gel 15%	

Not all drugs may be covered under every Plan.

If a drug is non-formulary on a Plan, documentation of medical necessity will be required.

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****

Member Name: _____

Member Optima #: _____ Date of Birth: _____

Prescriber Name: _____

Prescriber Signature: _____ Date: _____

Office Contact Name: _____

Phone Number: _____ Fax Number: _____

DEA OR NPI #: _____

*Approved by Pharmacy and Therapeutics Committee: 4/21/2016; 7/21/2022

REVISED/UPDATED: ~~5/9/2016; 12/20/2016; 8/19/2017; 12/7/2020; 6/7/2022~~ 8/22/2022